19011 Investors following Orchid Chemical. Share this News with them.
0
Like this story, share it with millions of investors on M3
Orchid Chem net sales up by 39.4% to Rs 332.69cr
Orchid Chemicals achieved a robust turnover and operating income of Rs 332.69 crore for Q3 FY07-08 in comparison to Rs 238.73 crore registered during the corresponding third quarter of last fiscal, growing by 39.4%.
Orchid Chemicals has announced third quarter numbers. It has posted 39.4% growth in its standalone net profit of Rs 54.12 crore for the quarter ended December 2007 as against Rs 28.32 crore in same period of last year.
Standalone net sales went up by 39.4% to Rs 332.69 crore from Rs 238.73 crore.
Key Takeaways from Orchid Chemicals:
Orchid Chemicals achieved a robust turnover and operating income of Rs 332.69 crore for Q3 FY07-08 in comparison to Rs 238.73 crore registered during the corresponding third quarter of last fiscal, growing by 39.4%.
EBIT stood at Rs 74.87 crore compared to Rs 54.28 crore.
Profit before tax grew by 97.5% and stood at Rs 61.78 crore as compared to Rs 31.28 crore
Net profit after tax grew by 91.1% and stood at Rs 54.12 crore
EPS grew to Rs 8.20 from Rs 4.31 of the corresponding period of last fiscal.
On a consolidated basis, Orchid's turnover for the quarter ended December 31, 2007 increased by 40% to Rs 347.38 crore
Orchid's US generics business contributed as much as 51% to the revenues during the third quarter of this fiscal. The two premium products (Cefepime & Cefdinir), which were launched during the earlier quarter continued to show steady growth in terms of sales and turnover.
The total count of ANDAs approved till date increased to 23, out of which 22 are in the Cephalosporin Segment and 1 in the NPNC segment.
